Biogen Idec Trading Nearly 2% Higher on Deutsche Bank Upgrade

by Benzinga Staff
June 21, 2011 10:47 AM | 11 seconds read |
Biogen Idec BIIB is trading nearly 2% higher on the Deutsche Bank's "Buy" upgrade earlier this morning. BIIB is currently trading at $100.62 per share. Biogen Idec Inc. is a global biotechnology company.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Intraday UpdateBiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!